

AMENDMENTS TO THE CLAIMS

1-23. (Previously cancelled)

24. (Currently canceled)

25-27. (Previously canceled)

28. (Currently canceled)

29. (Previously canceled).

30-36. (Currently canceled)

37-39. (Previously canceled).

40. (Currently canceled)

41. (Previously canceled).

42-43. (Currently canceled)

44-45. (Previously canceled)

46-49. (Currently canceled)

50. (New) A pharmaceutical composition for use in breast cancer therapy in humans, said composition comprising:

(a) at least one antineoplastic agent selected from the group consisting of epirubicin and docetaxel, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, or combination thereof; and

(b) aromatase inhibitor exemestane and a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, or combination thereof,

wherein said antineoplastic agent and said aromatase inhibitor are present in superadditive antitumor effective amounts.